GlaxoSmithKline

http://www.gsk.com

GlaxoSmithKline, Brentford Middlesex, United States of America.

We have a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative
GlaxoSmithKline - Company Profile

Ticker -
GSK - Financial Information

FDA Approves Cervarix, GlaxoSmithKline's Cervical Cancer Vaccine

Friday 16th of October 2009 11:25

About Cervical Cancer

Women are at risk of HPV infection and cervical cancer throughout their lives. Approximately 100 types of HPV have been identified to date and, of these, approximately 15 virus types are known to cause cervical cancer. While the majority of cervical cancers in North America are caused by HPV types 16 and 18, approximately 25 percent of all cervical cancers are caused by other oncogenic HPV types. Infection with cancer-causing virus types can lead to abnormal Pap tests, cervical pre-cancers, and cervical cancer.

Cervical cancer is the second leading cause of cancer death in women in their twenties and thirties. The American Cancer Society estimates that in 2009, in the U.S. approximately 11,000 women will be diagnosed with cervical cancer and 4,000 women will die from the disease, regardless of age. Worldwide, more than 500,000 women will be newly diagnosed with cervical cancer and 280,000 women will die from it each year.

GlaxoSmithKline Biologicals -- GSK Biologicals, GlaxoSmithKline's vaccines business, is one of the world's leading vaccine companies and a leader in innovation. The company is active in the fields of vaccine research, development and production with over 30 vaccines approved for marketing and 20 more in development. Headquartered in Belgium, GSK Biologicals has 13 manufacturing sites strategically positioned around the globe. In 2008, GSK Biologicals distributed 1.1 billion doses of vaccines to 176 countries in both the developed and the developing world -- an average of 3 million doses a day.

Through its accomplished and dedicated workforce, GSK Biologicals applies its expertise to discover innovative vaccines that contribute to the health and well-being of people of all generations around the world.

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

    Inquiries:

    US Media inquiries:                   Jeff McLaughlin       (919) 483 2839
                                          Sarah Alspach         (919) 483 2839
                                          Mary Anne Rhyne       (919) 483 2839
                                          Kevin Colgan          (919) 483 2839

    US Analyst/ Investor inquiries:       Tom Curry             (215) 751 5419
                                          Jen Hill Baxter       (215) 751 7002

    UK Media inquiries:                   Philip Thomson       (020) 8047 5502
                                          Claire Brough        (020) 8047 5502
                                          Stephen Rea          (020) 8047 5502
                                          Alexandra Harrison   (020) 8047 5502
                                          Gwenan White         (020) 8047 5502

    European Analyst/Investor inquiries:  David Mawdsley       (020) 8047 5564
                                          Sally Ferguson       (020) 8047 5543
                                          Gary Davies          (020) 8047 5503

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2008.

SOURCE GlaxoSmithKline

Source PR Newswire


www.prnewswire.co.uk

Browse news from 2009

Download PDF